Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$10.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

R&I affirms KAKEN PHARMACEUTICAL’s rating at "A-" and rating outlook stable


Friday, 25 Apr 2014 02:00am EDT 

KAKEN PHARMACEUTICAL CO LTD:Rating and Investment Information, Inc. (R&I) has affirmed the rating on the company at "A-".The rating outlook is stable. 

Company Quote

2357.0
-73.0 -3.00%
1:00am EST